Elizabeth S. Eaton

@LaboratoryLiz

Staff Writer covering preclinical science, policy, and everything in between

Vrijeme pridruživanja: srpanj 2018.

Tweetovi

Blokirali ste korisnika/cu @LaboratoryLiz

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LaboratoryLiz

  1. . CEO O’Day says patients will be focus of its response, not patents

    Poništi
  2. 5. velj

    And here's our table tallying ongoing trials of therapeutics to treat

    Prikaži ovu nit
    Poništi
  3. 5. velj

    3. Gilead says it's "investing pretty heavily" and working “night and day” to ramp up manufacturing for 4. says is the most promising candidate to treat

    Prikaži ovu nit
    Poništi
  4. 5. velj

    A newsy couple of days for and its antiviral to treat : 1. almost completely resolves symptoms of U.S. patient 2. plans to enroll patients in 2 Chinese trials mid-Feb

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet
    4. velj

    Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. All BioCentury coverage of the outbreak is in front of the paywall at .

    Poništi
  6. 17. sij

    Before kicked off this week, I spoke with CEO Blatt about the company's $125M series B and its three different approaches to treat

    Poništi
  7. 10. pro 2019.

    Ehsan Bahrami told he was blocked from traveling to the U.S. for because he is Iranian. His team won an Achievement Award for an abstract on the use of a screen in cells from patients

    Poništi
  8. proslijedio/la je Tweet
    1. lis 2019.
    Poništi
  9. proslijedio/la je Tweet
    6. kol 2019.

    AveXis knew about Zolgensma data manipulation and didn't tell FDA. SMA gene therapy will stay on the market, but a blow to as FDA weighs possible criminal/civil penalties

    Poništi
  10. 26. srp 2019.

    .'s spoke with , which said there were important differences in USC's AAV manufacturing, which are "key to efficiency"

    Poništi
  11. proslijedio/la je Tweet
    11. srp 2019.
    Poništi
  12. proslijedio/la je Tweet
    19. lip 2019.

    Great Emerging Company Profile from on Sherlock Biosciences and its mission to leverage and to rapidly and accurately detect disease. Read here

    Poništi
  13. proslijedio/la je Tweet
    14. lip 2019.

    Warning! Someone is mimicking BioCentury's Twitter page on the domain , to trick people into disclosing their Twitter credentials. The creators of that page are likely sending fake Twitter emails directing them to the site. Please take care.

    Poništi
  14. 10. lip 2019.
    Prikaži ovu nit
    Poništi
  15. 10. lip 2019.

    Some highlights from today's debate: speaks in favor of : "The government needs to step in and help." says she has "a moral obligation" to consider options other than deal w/

    Prikaži ovu nit
    Poništi
  16. 7. lip 2019.
    Poništi
  17. 4. lip 2019.

    The latest on in the U.K: Parents of children with have formed a buyer's club to purchase generic versions of and from an outside manufacturer, with eyes on a Crown Use License

    Poništi
  18. 31. svi 2019.

    I spoke with CEO Jing Watnick about how its lead candidate reprograms macrophages, induces apoptosis and increases T cell infiltration to treat cancer. The co has raised $27.5M from , and is now on the hunt for a ~$50M series C

    Poništi
  19. proslijedio/la je Tweet
    30. svi 2019.

    On the eve of , Thrive launches with $110M series A to take on big hitters , and develop a liquid biopsy test for the primary care setting. reports in the latest

    Poništi
  20. 24. svi 2019.

    In its response to the offer, says it's the "same annual spend" and took issue with how NHS characterized the negotiations, hinting that the end may *not* be in sight for the impasse

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·